A Randomized Controlled Trial of Chinese Medicine on Nonmotor Symptoms in Parkinson’s Disease
Table 1
Baseline characteristics.
Parameter
JLT group
Control group
p value
Age (years)
63.48 ± 9.72
63.31 ± 8.20
0.919
Gender (M/F)
35/21
38/17
0.464
Disease duration (years)
6.42 ± 4.15
5.42 ± 3.77
0.096
Duration of Levodopa treatment (years)
5.17 ± 4.42
3.94 ± 3.13
0.187
Total Levodopa dosage (mg/day)
459.82 ± 350.90
374.55 ± 257.46
0.148
Medication use
Levodopa, n (%)
53 (94.6)
50 (90.9)
0.447
Dopaminergic agonist, n (%)
23 (41.1)
17 (30.9)
0.265
Anticholinergic, n (%)
18 (32.1)
21 (38.2)
0.505
COMT inhibitor, n (%)
14 (25.0)
4 (7.3)
0.011
MAO-B inhibitor, n (%)
17 (30.4)
12 (21.8)
0.306
Amantadine, n (%)
5 (8.9)
4 (7.3)
0.749
Senna, n (%)
5 (8.9)
6 (10.9)
0.727
Lactulose, n (%)
4 (7.1)
3 (5.5)
0.714
Baseline scores
H&Y score
2.07 ± 0.60
2.02 ± 0.59
0.639
NMSS total
65.52 ± 49.77
47.42 ± 35.70
0.030
MDS-UPDRS part I
10.21 ± 7.06
8.76 ± 6.63
0.267
MDS-UPDRS part II
14.71 ± 7.95
11.58 ± 7.51
0.035
MDS-UPDRS part III
33.21 ± 15.39
33.27 ± 14.27
0.983
MDS-UPDRS part IV
4.00 ± 4.45
2.78 ± 3.70
0.120
Data are expressed as mean ± S.D; p value was comparing the difference between two groups in baseline; treatment group compared with placebo group by independent t-test; treatment group compared with placebo group by Chi-square test with continuity correction.
